LifeTech Scientific (1302) Fundamentals 2026 — P/E 37.2x, Revenue Analysis | SniperIQ

.42 on the HKSE. This SniperIQ fundamentals page covers LifeTech Scientific's valuation (P/E 37.2x, P/B 1.6x), profitability (net margin 10.8%), revenue (¥1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is LifeTech Scientific's market cap?

LifeTech Scientific (1302) has a market capitalization of approximately HK$6.2B, trading at HK

.42 on the HKSE. Market cap moves with the live share price.

What is LifeTech Scientific's P/E ratio?

LifeTech Scientific's trailing twelve-month P/E ratio is 37.2x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is LifeTech Scientific?

LifeTech Scientific runs a net profit margin of 10.8%, a gross margin of 74.4%, and an operating margin of 13.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does LifeTech Scientific generate?

LifeTech Scientific reported revenue of ¥1.4B for fiscal year 2025, with net income of ¥148M and earnings per share (EPS) of 0.033. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does LifeTech Scientific pay a dividend?

LifeTech Scientific does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is LifeTech Scientific financially healthy?

LifeTech Scientific carries a debt-to-equity ratio of 0.00x and a current ratio of 1.57x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is LifeTech Scientific a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LifeTech Scientific (1302) the key facts are: market cap HK$6.2B, P/E 37.2x, revenue ¥1.4B, 52-week range 1.3-2.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.